Bruker Microbiology & Infection Diagnostics Division Launches Mygenius Pro High-Throughput Sample-To-Answer Molecular Diagnostics System

Published: 2026-04-17 07:20:31 ET BRKR

Published on 04/17/2026 at 07:20 am EDT

Bruker Microbiology & Infection Diagnostics division announced the European launch of MyGenius PRO, a fully automated, sample-to-answer molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO automates the entire workflow - from patient sample to diagnostic result - enhancing laboratory efficiency and supporting higher-throughput volume testing needs.

MyGenius PRO installed at a European transplant center supporting routine infectious disease testing. At launch, the MyGenius PRO IVDR menu will include assays for Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) from whole blood, and BK virus (BKV) from urine, supporting diagnostic testing in immunocompromised patients. Rapid menu expansion, including Human Immunodeficiency Virus type 1 (HIV-1), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Herpesvirus 6 (HHV-6) IVDR assays, and additional sample matrices, are planned throughout 2026.

The MyGenius PRO platform was developed in a collaboration between ELITechGroup, a Bruker company, and Hitachi High Tech-Corporation (Hitachi High-Tech), combining complementary expertise in molecular assays, automation and engineering. Hitachi High-Tech will introduce the platform under the tradename LABOSPECT GA-5 in Japan. This system comes with Bruker molecular diagnostic assays for infectious disease testing in accordance with Japanese diagnostic regulations.

The launch of MyGenius PRO marks a new chapter in Bruker?s Microbiology & Infection Diagnostics molecular diagnostics strategy, further expanding a portfolio that includes InGenius, BeGenius, a rapidly growing CE-IVD assay menu, and novel LiquidArray assays for advanced multiplexing and more affordable syndromic panel testing.